Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 8

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements

Authors Yang F, Stewart M, Ye J, DeMets D

Received 5 March 2015

Accepted for publication 4 May 2015

Published 20 July 2015 Volume 2015:8 Pages 315—325

DOI https://doi.org/10.2147/DMSO.S84005

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Ming-Hui Zou


Fred Yang,1 Murray Stewart,2 June Ye,2 David DeMets3

1AstraZeneca, Gaithersburg, MD, USA; 2GlaxoSmithKline, Upper Merion, PA, USA; 3Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison, WI, USA


Abstract: For type 2 diabetes mellitus treatment and clinical development, proper evaluation of cardiovascular risk has been required by regulatory agencies (eg, the US Food and Drug Administration) since cardiovascular safety is very important in this patient population. The US Food and Drug Administration issued general guidelines for cardiovascular safety evaluation that outlined the requirements considered adequate for cardiovascular safety evaluation. However, there are multiple options to obtain the data and fulfill these requirements. In this paper, we outline the potential pathways and challenges in various aspects of cardiovascular safety evaluation in type 2 diabetes clinical development, including study design, populations, and endpoints. Specifically, we discuss some challenges in statistical analysis which have implications for the design, implementation, and interpretation of these outcome studies.

Keywords: T2DM, cardiovascular outcome, CV risk, noninferiority, superiority, major adverse cardiac event

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]